English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The authors describe a patient with personal and family history of muscle pains highly suggestive of mitochondrial disease. She presented with familial combined hyperlipidaemia with family history of premature coronary artery disease. After 4-week therapy of 5 mg of rosuvastatin once a week combined with 10 mg of ezetimibe daily, the low-density lipoprotein cholesterol level was markedly decreased from 3.88 to 2.82 mmol/l (27.3% reduction). She has experienced no adverse effects after 6 month treatment. The results suggest that the combination therapy of low-dose once-weekly rosuvastatin and daily ezetimibe could be used as an effective regimen for patients with mitochondrial disease.

Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease